Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by JMark80on Nov 17, 2019 5:36pm

46 Views

Post# 30362247

RE:RE:RE:RE:Why KLY is Worth the Wait

Justforfun10 wrote: Not sure if olive oil as the medium in the CBD formulation is the chief ingredient that addresses the bioavailability issue of CBD beyond the liver and the stability of the CBD formulation issue but nonetheless the patent covers the use of it for prevention of acute GVHD.

Good question. Olive oil is a common carrier and what Talent used in their phase 2a studies. I don't know what, if anything, makes Kalytera's formulation novel and proprietary.

Bullboard Posts

Fobi AI responds to cease trade order, filing delay “disappointing”